RxDoctor Payments DataLook up a doctor →

Afton Dickerson, NP

Acute Care · Houston, TXNPI 1497387393

Payments from drug & device makers

$27,390in general payments, 2019–2025

Across 854 payments — averaging $32.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4K
  • Johnson & Johnson$2K
  • AstraZeneca$2K
  • Merck$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Bristol Myers Squibb$1K
  • plus $15K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis96$3,710
Johnson & Johnson(2 entities)70$2,166
AstraZeneca(2 entities)48$1,914
Merck54$1,518
E.r. Squibb & Sons, L.L.C.41$1,512
Bristol Myers Squibb49$1,279
AbbVie27$1,080
Eisai Inc.29$984
GSK22$845
Sanofi30$826
Astellas Pharma US Inc22$775
Lilly USA, LLC23$738
Incyte Corporation22$646
Seagen Inc.19$630
Amgen21$550
Gilead12$505
Genentech USA, Inc.17$454
Pfizer12$333
Takeda Pharmaceuticals U.S.A., Inc.15$326
Jazz Pharmaceuticals Inc.9$320
Deciphera Pharmaceuticals Inc.12$319
Rigel Pharmaceuticals, Inc.13$319
Sobi, Inc6$308
Springworks Therapeutics, Inc.15$300
Bayer13$294
Regeneron Healthcare Solutions, Inc.4$278
Pharmacyclics LLC, An Abbvie Company10$272
Morphosys, US Inc.11$223
Janssen Scientific Affairs, LLC2$222
Taiho Oncology, Inc.11$205
Beigene USA, Inc.4$204
Pharmaessentia USA Corporation8$195
Daiichi Sankyo Inc.5$190
Myriad Genetic Laboratories, Inc.2$187
Karyopharm Therapeutics Inc.4$171
Pharmacosmos Therapeutics Inc.3$165
Ipsen Biopharmaceuticals, Inc7$152
Immunocore Limited3$148
Puma Biotechnology, Inc.4$134
Apellis Pharmaceuticals, Inc.5$129
Adaptive Biotechnologies Corporation6$124
TG Therapeutics, Inc.2$122
CTI Biopharma Corp.5$120
Sanofi-aventis U.S. LLC2$115
BTG International Inc.1$97
Exelixis Inc.5$88
Blueprint Medicines Corporation3$80
Array Biopharma Inc3$79
Geron Corporation3$76
Servier Pharmaceuticals LLC4$76
Mirati Therapeutics, Inc.4$70
ADC Therapeutics America, Inc.3$68
Stemline Therapeutics Inc.3$66
G1 Therapeutics, Inc.3$65
Myovant Sciences Inc.2$55
ASD Specialty Healthcare, LLC1$49
Alnylam Pharmaceuticals Inc.2$46
Boston Scientific2$45
Tempus AI, Inc2$44
Kyowa Kirin, Inc.2$43

How this compares

$27,390 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas →

Medicare billing

Part B allowed, 2024
$17,363
Medicare patients
96
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →